APA (7th ed.) Citation

Anderson, K. G., Su, Y., Burnett, M. G., Bates, B. M., Suarez Gutierrez, M. L., Ruskin, S. L., . . . Greenberg, P. D. (2023). 803 Triple checkpoint blockade, but not anti-PD1 alone, enhances the efficacy of engineered adoptive T cell therapy in advanced ovarian cancer. Journal for immunotherapy of cancer, 11(Suppl 1), A902. https://doi.org/10.1136/jitc-2023-SITC2023.0803

Chicago Style (17th ed.) Citation

Anderson, Kristin G., Yapeng Su, Madison G. Burnett, Breanna M. Bates, Magdalia L. Suarez Gutierrez, Susan L. Ruskin, Valentin Voillet, Raphael Gottardo, and Philip D. Greenberg. "803 Triple Checkpoint Blockade, but Not Anti-PD1 Alone, Enhances the Efficacy of Engineered Adoptive T Cell Therapy in Advanced Ovarian Cancer." Journal for Immunotherapy of Cancer 11, no. Suppl 1 (2023): A902. https://doi.org/10.1136/jitc-2023-SITC2023.0803.

MLA (9th ed.) Citation

Anderson, Kristin G., et al. "803 Triple Checkpoint Blockade, but Not Anti-PD1 Alone, Enhances the Efficacy of Engineered Adoptive T Cell Therapy in Advanced Ovarian Cancer." Journal for Immunotherapy of Cancer, vol. 11, no. Suppl 1, 2023, p. A902, https://doi.org/10.1136/jitc-2023-SITC2023.0803.